Stock Analysis
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis
Ultragenyx Pharmaceutical Inc. (RARE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Ultragenyx Pharmaceutical Inc. (RARE) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 64/100. Risk is the weakest current factor at 21/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RARE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $14.30 |
| AIQ Score | 43/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.54B |
| P/E Ratio | -4.42 |
| Forward P/E | — |
| EPS | -$0.90 |
| Revenue TTM | $214M |
| Dividend Yield | 0.00% |
| Beta | 0.31 |
| Volume | 3.25M |
| 52-week range | $13.81-$39.89 |
| RSI 14 | 15.54 |
| 50-Day SMA | $26.32 |
| 200-Day SMA | $25.64 |
| Analyst Price Target | $36.45 |
| Next Earnings | Nov 3, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
RARE
OverviewRARE Stock Analysis Summary
Ultragenyx Pharmaceutical Inc. (RARE) currently has an AIQ Score of 43/100, indicating a neutral setup. Quality is the strongest factor at 64/100. Risk resilience is the weakest current factor at 21/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, RARE has AIQ Score of 43/100 with Quality base of 64/100 and fading Risk resilience at 21/100. Wait for component alignment before adding exposure.
Quality (64/100) leads while Risk resilience (21/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.69% stock move · RARE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RARE Bullish or Bearish Right Now?
RARE currently has a neutral overall setup. Quality is the strongest factor at 64/100, while Risk Resilience is weakest at 21/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 64/100.
- - Analyst target implies +154.90% upside from the latest quote.
- - Momentum is weak at 22/100.
- - Risk Resilience is weak at 21/100.
- - Price is -44.22% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (36 vs 8).
Current Consensus
RARE's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 1 neutral, and 36 sell votes. RARE's 14-day RSI is 15.54, which places the stock in an oversold momentum range. RARE's beta is 0.31, indicating lower market sensitivity than the broad market.
What Changed in RARE?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the RARE Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RARE Decision Framework
Public evidence layers, setup checks, and risk context for Ultragenyx Pharmaceutical Inc..
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis
Ultragenyx Pharmaceutical Inc. has an AIQ Score of 43/100 in a Neutral regime. Quality is strongest at 64/100. Beta is not shown in the current snapshot. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RARE is in a Neutral AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that quality leads at 64/100 while risk lags at 21/100. |
| Factor Evidence | Momentum 22/100 · Value 50/100 · Quality 64/100 · Risk 21/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 64/100.
Momentum is 22/100 and RSI (14) is 15.5.
RARE is in a Neutral regime at 43/100.
Risk factor is 21/100 and annual volatility 80.54%.
Current conflict: quality leads at 64/100 while risk lags at 21/100.
RARE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RARE Fundamentals
RARE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RARE Technical Analysis
RARE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RARE Stock Catalysts
Track RARE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RARE Dividend Analysis
RARE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RARE Financial Data
RARE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RARE Risk Analysis
RARE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RARE Stock News
RARE stock news, market tone, recent headlines, and catalyst context.
RARE vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: RARE · RCKT · RGNX · RIGL · ROIV. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RARE Current stock | 43/100 | 50/100 | 22/100 | 21/100 | -0.52 | 80.54% | Current |
| RCKT Rocket Pharmaceuticals | 36/100 | — | 37/100 | 48/100 | 0.37 | 71.62% | RARE vs RCKT |
| RGNX REGENXBIO | 44/100 | 56/100 | 26/100 | 55/100 | 0.33 | 93.31% | RARE vs RGNX |
| RIGL Rigel Pharmaceuticals | 74/100 | 63/100 | 67/100 | 59/100 | 0.65 | 64.58% | RARE vs RIGL |
| ROIV Roivant Sciences | 57/100 | 34/100 | 78/100 | 61/100 | 2.48 | 46.57% | RARE vs ROIV |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RARE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RARE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RARE Stock FAQ
What is RARE stock price today?
Ultragenyx Pharmaceutical Inc.'s current stock price is $14.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RARE bullish or bearish right now?
RARE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RARE's market cap?
RARE's market cap is $2.54B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RARE's current P/E ratio?
RARE's current P/E ratio is -4.42 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RARE's RSI?
RARE's 14-day RSI is 15.54 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RARE above its 50-day and 200-day moving averages?
RARE is -45.68% from its 50-day SMA and -44.22% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RARE's next earnings date?
RARE's next earnings date is currently listed as Nov 3, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RARE pay a dividend?
RARE's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.